Introduction

Ulcerative colitis and Crohn’s disease represent two entities of inflammatory disease of the large and small intestine whose aetiology and inter-relationships are not yet known. Their course is both acute and chronic, with unpredictable remissions and exacerbations, many local and systemic complications, and variable response to therapy. Progress in understanding the pathogenesis of ulcerative colitis and Crohn’s disease has been hampered by the intrinsic complexity of the diseases and their variable manifestations, which serve to make the distinction between essential and non-essential features difficult. Another important limitation in the study and understanding of the diseases has been the lack of suitable animal models.  

Despite this, immunoregulation and lymphocyte function in patients with ulcerative colitis has been reported to be abnormal, suggesting that it may be an autoimmune disorder. Moreover metabolites of arachidonic acid seem to be implicated in the pathogenesis of inflammatory bowel diseases. Cyclooxygenase as well as lipoxygenase metabolites have been reported to be increased in patients with ulcerative colitis or Crohn’s disease. The anti-inflammatory properties of prostaglandin E2 (PGE2) are well described, in contrast to the pro-inflammatory action of leukotriene B4 (LTB4), whereas several eicosanoids are involved in the feed-back mechanisms of the arachidonic acid cascade. In the present study the metabolism of arachidonic acid in inflamed mucosal tissue taken from an animal model of inflammatory bowel disease (IBD) was investigated in order to elucidate further the involvement of arachidonic acid metabolites in inflammatory bowel disease. In a previous study, it was shown that the level of ex vivo released immunoreactive LTB4 was elevated in inflamed distal small intestine taken from rats with TNBS-induced chronic enteritis. In the present study the balance between cyclooxygenase and lipoxygenase metabolites formed by rat distal small intestine has been investigated. Furthermore, the validity of this model was investigated by examining the effects of 5-aminosalicylic acid (5-ASA), on both the enteritis score and the ratio of pro- and anti-inflammatory products formed.

Materials and Methods

Induction of enteritis: Inflammation of the rat distal small intestine was induced by a method previously described in detail. Female rats (150–200 g) were sensitized by intradermal injection of 0.05 ml of 0.8% 2,4,6-trinitrobenzenesulphonic acid (TNBS) into their back once daily for 3 consecutive days.
After 18 days the animals received a further intradermal booster injection (0.05 ml). After a further 10 days the animals were challenged once daily for 21 consecutive days by intrajejunal application of a 0.08% TNBS preparation (0.2 mg/rat) via an implanted catheter. Drug treatment with 5-ASA (4.64, 10.0, 21.5 and 46.4 mg/kg/day; Heraeus, Karlsruhe, Germany) was performed by oral application twice a day starting 6 h before the first local TNBS administration and was continued for 3 weeks, the last drug application being performed 6 h before the last TNBS administration. 5-ASA was suspended in 1% carboxymethylcellulose. Each group consisted of ten rats.

Working up method of distal small intestine: Rats were killed by CO₂ asphyxiation 24 h after the last intraluminal application of TNBS at day 0, 1, 2, 4, 7, 14 and 21. The distal 10 cm of small intestine were dissected out and immediately assessed by two independent observers for inflammation using a macroscopic enteritis score of value 0-3, defined as no (0), slight (1), intermediate (2) or intense (3) redness of the intestine. 11,12 Segments of precisely 10 cm were rinsed in saline and weighed as a parameter of oedema or granuloma formation. Segments of inflamed and control distal small intestine were histologically examined for qualitative confirmation of the visual assessment of inflammation.

Eicosanoid metabolism and determinations: To determine eicosanoid reduction of the inflamed mucosa, tissue samples of distal small intestine were homogenized in Krebs' buffer by means of an Ultra-Turrax, incubated for 10 min with 0.125 μCi [14C]-arachidonic acid and stimulated with Ca-ionophore A23187 (2 μM). 9 The 14C-labelled eicosanoids formed were separated by HPLC and measured by on-line beta detection. 13 Total protein content of any tissue sample was determined. 14

Data handling: Data obtained by comparison of enteritis score, gut weight, protein content and formation of arachidonic acid metabolites, expressed as mean ± S.E.M. of 10 experiments per group, were statistically analysed by Mann-Whitney U-test; values of p ≤ 0.05 being considered as significant.

Results

Enteritis score: A rapid increase of the enteritis score was observed from day 0 to day 2, which did not further increase until day 21 of daily intrajejunal treatment with TNBS (Table 1). Histological examination of the gut samples confirmed the results obtained by macroscopic enteritis score. Remarkable changes in mucosal integrity and activation of Peyer's patches were induced. There was no significant difference between the TNBS groups from day 2 to day 14 of local TNBS treatment. Acute inflammatory response with a predominantly neutrophil infiltration was not detectable. The histology showed light to moderate signs of chronic inflammation with infiltration of mainly lymphocytes and histiocytes.

Body weight: Body weights were not significantly changed during intrajejunal implantation, TNBS challenge or 5-ASA treatment.

Gut weight: Gut weights of all 10 cm samples were similar during the time course of TNBS treatment within a range of 0.78 to 0.95 g/10 cm distal small intestine. No significant difference was observed between the different groups (data not shown).

Protein content: Protein content of all tissue samples taken from distal small intestine after different times of intrajejunal TNBS treatment was constant within a range of 11.8 to 14.2 μg/mg tissue and no significant differences were observed between the different groups (data not shown).

Arachidonic acid metabolite profile: The main results in determination of the time course of arachidonic acid metabolism were: (1) a slight increase of overall eicosanoid production after 1 day of TNBS treatment; (2) no change of metabolism after 1 to 14 days of intrajejunal TNBS treatment; and (3) a marked increase of eicosanoids after 21 days of TNBS treatment.

The greatest increase of eicosanoids was observed in the formation of TxB₂, PGD₂ and sulphidopeptide leukotrienes (S-LTs) (25-30-fold compared to controls, Figs 1, 2 and 3). Smaller increases were found for the PGE₂ (10-fold), 6kPGF₁₂, LTB₄, 12- and 15-HETE (5-fold...
Eicosanoids in chronic enteritis

Effects of 5-ASA: Oral treatment of the animals with 5-ASA dose-dependently reduced the enteritis score after 21 days of intraluminal application of TNBS (Table 1). Gut weight of distal small intestine of a defined length of 10 cm was slightly reduced by 5-ASA treatment. Both the increased cyclooxygenase and lipoxygenase production after 21 days of TNBS application was diminished to 40% of the production by 5-ASA treatment (see Figs 1–4, A-marked bars) still being a 2–4-fold increase compared to control values on day 0.

Discussion

In this study the authors found an increase in the metabolism of arachidonic acid by homogenates of inflamed distal small intestine taken from rats during chronic enteritis induced by the chemical hapten TNBS. In previous studies marked species differences in the production pattern of eicosanoids by inflammatory cells was shown. These differences also occur in inflamed and non-inflamed colonic tissue. In human inflammatory bowel disease mainly PGE2 and LTB4 were measured in dialysis fluid, whereas lately evidence was obtained that other lipoxygenase products, such as 15-HETE, are important mediators of inflammation. It is known that prostacyclin and 15-HETE are formed by endothelial cells. Probably during the type of inflammation used in this study these cells are not triggered to increase eicosanoid synthesis. The prostaglandins LTC4 and LTB4 normally are formed by macrophages, eosinophils and mast cells respectively. Thromboxane, however, is mainly formed by platelets and macrophages. In human colitis TXB2 formation was not increased sig-
significantly in colonic mucosa,9 whereas in experimental colitis marked elevation of thromboxane synthesis was only observed in rabbits after the induction of dinitrochlorobenzene (DNCB)8,19 and formyl-methionyl-leucyl-phenyalanine (FMLP).20 In acute inflammation a rapid influx of granulocytes is seen, followed by inflammatory cells such as macrophages. Although in histological sections the contribution of platelets was negligible, one should consider the potency of platelets in generating thromboxane.

Despite the variation of the different types of metabolites determined in this investigation following the time course, the results suggest a break-even point between 14 and 21 days of local intraluminal TNBS treatment. However, this does not correlate with the observed changes in entritis score and histological assessment of the distal small intestine after different times of TNBS treatment.

According to the normal time course of inflammatory reactions an early response characterized by acute inflammation and a late response characterized by chronic inflammation were expected during the time course of TNBS treatment. This was partly supported by the small initial increase in mediators and the exacerbation of mediator production after 21 days. This observation, however, was not confirmed by histologic observations as there was no detectable infiltration of neutrophils that would indicate an acute inflammatory response. The onset of inflammation on day 2 of TNBS treatment was characterized by infiltration of lymphocytes and histiocytes, indicating chronic inflammatory response directly after TNBS treatment. These results are somewhat unexpected, and future studies should include examination of changes in the first hours of local TNBS treatment.

In contrast to other immunologically induced chronic inflammation of the gut as animal models of IBD,8,21-26 chronicity of the inflammatory reaction in this model was induced by multiple instead of one21 or few22,25,26 local administrations of the immunogen. Another difference is a 3-week instead of 3-day22,25,26 time schedule for the local challenge procedure. This repeated and weak stimulation of the immune system by one specific immunogen may mimic the human disease more closely, and the model has more features in common with human IBDS than non-immunological and acute models.27 In contrast to the human disease the typical discontinuous time course and the mixture of chronic and acute inflammation28 were not induced in this model.

Oral 5-ASA (low dose, 4.64 mg/kg/day) during the 21-day TNBS treatment schedule clearly reduced eicosanoid formation, but resulted in only a slight decrease of approx. 15% in histological examination and symptom score. The entritis score, however, was dose-dependently decreased (Table 1), while a further inhibition of eicosanoid synthesis was not observed. An explanation for this could be that only a weak dose of 5-ASA is sufficient to influence AA metabolism, but that much higher doses are needed to counteract the severe signs of inflammation as was reflected in the macroscopic inflammation score. The time schedule of 5-ASA treatment in this investigation includes the whole time period of entritis induction by local TNBS administration. In order to answer the question of whether 5-ASA is effective on early or established inflammatory response of the distal small intestine in this model, further investigations with different time schedules of 5-ASA treatment have to be performed.

In conclusion, although this model has many features of Crohn’s disease, it is still not clear whether it is suitable for testing new drugs in IBD, especially those which are supposed to act as inhibitors of the arachidonic acid metabolism. These present findings indicate that eicosanoids are important mediators in the chronic phase of inflammatory bowel disease,29 probably in the regulation of the release of pro-inflammatory substances such as platelet activating factor (PAF),30 cytokines,31 LTBA,32 and LTDB.33 Further investigations with the use of nonspecific acting anti-inflammatory drugs, such as corticosteroids, could give more information about this sequential release of inflammatory mediators.

References


ACKNOWLEDGEMENT. The excellent technical assistance of Mr G. Haase is gratefully acknowledged.

Received 30 June 1993; accepted 12 August 1993.